2017,DPSCREEN: Dynamic Personalized Screening,Screening is important for the diagnosis and treatment of a wide variety of diseases.  A good screening  policy should be personalized to the disease  to the features of the patient and to the dynamic history of the patient (including the history of screening).  The growth of electronic health records data  has led to the development of many  models to  predict the onset and progression of different diseases. However  there has been limited work to address the personalized screening for these different diseases. In this work  we develop the first framework to construct screening policies for a large class of disease models. The disease is modeled as a finite state stochastic process with an absorbing disease state. The patient observes an  external information process (for instance  self-examinations  discovering comorbidities  etc.) which can trigger the patient to arrive at the clinician earlier than scheduled screenings. The clinician carries out the tests; based on the test results and the  external information it schedules the next arrival.  Computing the exactly optimal screening policy that balances the delay in the detection against the frequency of screenings is computationally intractable; this paper provides a computationally tractable construction of an approximately optimal policy.  As an illustration  we make use of a large breast cancer data set.  The constructed policy screens patients more or less often according to their initial risk -- it is personalized to the features of the patient -- and according to the results of previous screens â€“ it is personalized to the  history of the patient. In comparison with existing clinical policies  the constructed policy leads to large reductions (28-68 %) in the number of screens performed while achieving the same expected delays in disease detection.,DPSCREEN: Dynamic Personalized Screening

Kartik Ahuja

Electrical and Computer Engineering Department

University of California  Los Angeles

ahujak@ucla.edu

William R. Zame

Economics Department

University of California  Los Angeles

zame@econ.ucla.edu

Mihaela van der Schaar

Electrical and Computer Engineering Department  University of California  Los Angeles

Engineering Science Department  University of Oxford

mihaela.vanderschaar@oxford-man.ox.ac.uk

Abstract

Screening is important for the diagnosis and treatment of a wide variety of diseases.
A good screening policy should be personalized to the features of the patient
and to the dynamic history of the patient (including the history of screening).
The growth of electronic health records data has led to the development of many
models to predict the onset and progression of different diseases. However  there
has been limited work to address the personalized screening for these different
diseases. In this work  we develop the ï¬rst framework to construct screening
policies for a large class of disease models. The disease is modeled as a ï¬nite state
stochastic process with an absorbing disease state. The patient observes an external
information process (for instance  self-examinations  discovering comorbidities 
etc.) which can trigger the patient to arrive at the clinician earlier than scheduled
screenings. The clinician carries out the tests; based on the test results and the
external information it schedules the next arrival. Computing the exactly optimal
screening policy that balances the delay in the detection against the frequency of
screenings is computationally intractable; this paper provides a computationally
tractable construction of an approximately optimal policy. As an illustration  we
make use of a large breast cancer data set. The constructed policy screens patients
more or less often according to their initial risk â€“ it is personalized to the features
of the patient â€“ and according to the results of previous screens â€“ it is personalized
to the history of the patient. In comparison with existing clinical policies  the
constructed policy leads to large reductions (28-68%) in the number of screens
performed while achieving the same expected delays in disease detection.

Introduction

1
Screening plays an important role in the diagnosis and treatment of a wide variety of diseases 
including cancer  cardiovascular disease  HIV  diabetes and many others by leading to early detection
of disease [1]-[3]. For some diseases (e.g.  breast cancer  pancreatic cancer)  the beneï¬t of early
detection is enormous [4] [5]. Because screening â€“ especially screening that requires invasive
procedures such as mammograms  CT scans  biopsies  angiograms  etc. â€“ imposes ï¬nancial and
health costs on the patient and resource costs on society  good screening policies should trade off
beneï¬t and cost [6]. The best screening policies should take into account that the trade-off between
beneï¬t and cost should be different for different diseases â€“ but also for different patients â€“ patients
whose features suggest that they are at high risk should be screened more often; patients whose
features suggest that they are at low risk should be screened less often â€“ and even different for the
same individual at different points in time  as the perceived risk for that patient changes. Thus the

31st Conference on Neural Information Processing Systems (NIPS 2017)  Long Beach  CA  USA.

best screening policies should account for the disease type and be personalized to the features of the
patient and to the history of the patient (including the history of screening) [32]. This paper develops
the ï¬rst such personalized screening policies in a very general setting.
A screening policy prescribes what tests should/should not be done and when. Developing person-
alized screening policies that optimally balance the frequency of testing against the delay in the
detection of the disease is extremely difï¬cult for a number of reasons. (1) The onset and progression
of different diseases varies signiï¬cantly across the diseases. For instance  in [7] the development of
breast cancer is modeled as a stationary Markov process  in [36] the development of HIV is modeled
using a non-stationary survival process and  in [46] the development of colon cancer is modeled as a
Semi-Markov process. The test outcomes observed over time may follow a non-stationary stochastic
process that depends on the disease process upto that time and the features of the patient [35][36].
Existing works on screening [7] [9] are restricted to Markov disease processes and stationary Markov
test outcome models  while this is not the case for many diseases and their test outcomes [10][35]-[37].
(2) The cost of not screening is the delay in detection of disease  which is not known. Hence the
decision maker must act on the basis of beliefs about future disease states in addition to beliefs about
the current disease state. (3) Patients can arrive at the scheduled time but may also arrive earlier on
the basis of external information so the decision makerâ€™s beliefs must take this external information
into account. For instance  external information can be the development of lumps on breasts [25][26] 
or the development of a comorbidity [33][41]. (4) Given models of the progression of the disease and
of the external information  solving for that policy is computationally intractable in general.
This paper addresses all of these problems. We provide a computationally effective procedure that
solves for an approximately optimal policy and we provide bounds for the approximation error (loss
in performance) that arises from using the approximately optimal policy rather than the exactly
optimal policy. Our procedure is applicable to many disease models such as dynamic survival models
[11]-[13][36]-[37]  ï¬rst hitting time models [7][9][14]-[17].
Evaluating a proposed personalized screening policy using observational data is challenging. Obser-
vational data does not contain the counterfactuals: we cannot know what would have happened if a
patient had been screened more often or an additional test had been performed. Instead  we follow an
alternative route that has become standard in the literature [7]-[10]: we learn the disease progression
model from the observational data and then evaluate the screening policy on the basis of the learned
model. We also account for the fact that the disease model may be incorrectly estimated. We show
that if the estimation error and the approximation error are small  then the policy we construct is very
close to the policy for the correctly estimated model.
In this work  use of a large breast cancer data set to illustrate the proposed personalized screening
policy. We show that high risk patients are screened more often than low risk patients (personalization
to the features of the patient) and that patients with bad test results are screened more often than
patients with good test results (personalization to the dynamic history of the patient). The effect of
these personalizations is that  in comparison with existing clinical policies  the policy we construct
leads to large reductions (28-68%) in screening while achieving the same expected delays in disease
detection. To illustrate the impact of the disease on the policy  we carry out a synthetic exercise across
diseases  one for which the delay cost is linear and one for which the delay cost is quadratic. We
show that the regime of operation (frequency of tests vs expected delay in detection) for the policies
for the two costs are signiï¬cantly different  thus highlighting the importance of choice of costs.

2 Model and Problem Formulation
Time Time is discrete and the time horizon is ï¬nite; we write T = {1  ...  T} for the set of time slots.
Patient Features Patients are distinguished by a (ï¬xed) feature x. We assume that the features of a
patient (age  sex  family history  etc.) are observable and that the set X of all patient features is ï¬nite.
Disease Model We model the disease in terms of the (true physiological) state  where the state space
is S. The disease follows a ï¬nite state stochastic process; S T is the space of state trajectories. The
probability distribution over trajectories depends on the patientâ€™s features; for (cid:126)s âˆˆ S T   x âˆˆ X we
write P r((cid:126)s|x) for the probability that the state trajectory is (cid:126)s given that the patientâ€™s features are
x. We distinguish one state D âˆˆ S as the disease state; the disease state D is absorbing.1 Hence

1The restriction to a single absorbing disease state is only for expositional convenience.

2

P r(s(t) = D  s(t(cid:48)) (cid:54)= D) = 0 for every time t and every time t(cid:48) > t. The true state is hidden/not
observed.2
Our stochastic process model of disease encompasses many of the disease models in the literature 
including discrete time survival models. The (discrete time) Cox Proportional Odds model [11]  for
instance  is the particular case of our model in which there are two states (Healthy H and Disease
D) and the probability distribution over state trajectories is determined from the hazard rates. To
be precise: if (cid:126)s is the state trajectory for which the disease state ï¬rst occurs at time t0  so that
s(t) = H for t < t0 and s(t) = D for t â‰¥ t0  Î»(t|x) is the hazard at time t conditional on x  then
P r((cid:126)s|x) = [1âˆ’ Î»(1|x)]Â·Â·Â· [1âˆ’ Î»(t0 âˆ’ 1|x)][Î»(t0|x)] and P r((cid:126)s|x) = 0 for all trajectories not having
this form. Similar constructions show that other dynamic survival models [14]-[17] [10][37] also ï¬t
in the rubric of the general model presented here.3
External Information The clinician performs tests that are informative about the patientâ€™s true
state; in addition  external information may also arrive (for instance  patient self-examines breasts for
lumps  patient discovers comorbidities  etc.). The patient observes an external information process
modeled by a ï¬nite state stochastic process with state space Y; the information at time t is Y (t) âˆˆ Y
(for instance  Y = {Lump  No Lump}). If the patient visits clinician at time t  then this external
information Y (t) arrives to the clinician. Y (t) may be correlated with the patientâ€™s state trajectory
through time t and the patientâ€™s features; we write P r(Y (t) = y|(cid:126)s(t)  x) for the probability that
the external information at time t is y âˆˆ Y  conditional on the state trajectory through time t and
features x. We assume that at each time t the external information Y (t) is independent of the past
observations conditional on the state trajectory through time t  (cid:126)s(t)  and features x.
Arrival The patient visits the clinician at time t if either (a) the information process Y (t) exceeds
some threshold Ëœy or (b) t is the time for the next recommended screening (determined in the Screening
Policies described below). The ï¬rst visit of the patient to the hospital depends on the screening
policy and the patientâ€™s features (See the description below). If the patient visits the clinician at time
t  the clinician performs a sequence of tests and observes the results. For simplicity of exposition 
we assume that the clinician performs only a single test  with a ï¬nite set Z of outcomes. We write
P r(Z(t) = z|(cid:126)s(t)  x) as the probability that test performed at time t yields the result z  conditional
on the (unobserved) state trajectory and the patientâ€™s features. We assume that the current test result
is independent of past test results  conditional on the state trajectory and patient features. We also
assume that current test result is independent of the external information conditional on the state
trajectory through time t and the patient features. These assumptions are standard [7] [36]. We
adopt the convention that z(t) = âˆ… if the patient does not visit the clinician at time t so that no test
is performed. If the test outcome z âˆˆ Z + âŠ‚ Z  then the patient is diagnosed to have the disease.
We assume that there are no false positives. If a patient is diagnosed to be in the disease state  then
screening ends and treatment begins.
Screening Policies The history of a patient through time t consists of the trajectories of external
information  test results and screening recommendations through time t. Write H(t) for the set of
t=0 H(t) for the set of all histories. By convention H(0) consists
only of the empty history. A screening policy is a map Ï€ : X Ã—H â†’ {1  . . .   T}âˆª{D} that speciï¬es 
for each feature x and history h either the next screening time t+ or the decision that the patient is in
the disease state D and so treatment should begin. A screening policy Ï€ begins at time 0  when the
history is empty  so Ï€(x âˆ…) speciï¬es the ï¬rst screening time for a patient with features x. (For riskier
patients  screening should begin earlier.) Write Î  for the space of all screening policies.
Screening Cost We normalize so that the cost of each screening is 1. (We can easily generalize to
the more general setting in which the clinician decides from multiple tests [50]  and different tests
have different costs.) The cost of screening is a proxy for some combination of the monetary cost  the
resource cost and the health cost to the patient. We discount screening costs over time so if Ts is the
Î´t  where Î´ âˆˆ (0  1).

set of times at which the patient is screened then the screening cost is(cid:80)

histories through time t and H =(cid:83)T

tâˆˆTs

2For many diseases  it seems natural to identify states intermediate between Healthy and Disease. For
instance  because breast lumps [26] or colon polyps [9] that are found to be benign may become malignant  it
seems natural to distinguish at least one Risky state  intermediate between the Healthy and Disease states.

3We can encompass the possibility of competing risks (e.g.  different kinds of heart failure) [13] simply by

allowing for multiple absorbing states.

3

Delay Cost
If disease ï¬rst occurs at time tD (the incidence time) but is detected only at time
td > tD (the detection time) then the patient incurs a delay cost C(td âˆ’ tD; tD). If the disease
is never detected the delay cost is C(T âˆ’ tD; tD). We assume that the delay cost function C :
{1  . . .   T} Ã— {1  . . .   T âˆ’ 1} â†’ (0 âˆ) is increasing in the ï¬rst argument (the lag in detection)
and decreasing in the second argument (the incidence time). The cost of delay is 0 if disease never
occurs or occurs only at time t = T . Note that as soon as the disease is detected screening ends
and treatment begins; in particular  there is a single unique time of incidence and a single unique
time of detection. We allow for general delay costs because the impact of early/late detection on the
probability of survival/successful treatment is different for different diseases.
Expected Costs If the patient features are x âˆˆ X then every screening policy Ï€ âˆˆ Î  induces a
probability distribution P r(Â·|x  Ï€) on the space H(T ) of all histories through time T and in particular
induces probability distributions Ïƒ = P r(Â·|x  Ï€) on the families Ts âŠ‚ 2{1 ... Tâˆ’1} of screening times
and Î² = P r((Â· Â·)|x  Ï€) on the pairs (tD  td) of incidence time and detection time. The expected
screening cost is EÏƒ
graphical model for the entire setup in the Appendix B of the Supplementary Materials.
Optimal Screening Policy The objective of the screening policy is to minimize a weighted sum of
the screening cost and the delay cost; i.e. the optimal screening policy is deï¬ned by

Î´t(cid:3) and the expected delay cost is EÎ²
(cid:110)

(cid:2)C(td âˆ’ tD  tD)(cid:3). We provide a

(cid:2)(cid:80)

(cid:111)

tâˆˆTs

(1)

arg min
Ï€âˆˆÎ 

(1 âˆ’ w) EÏƒ

+ wEÎ²[C(td âˆ’ tD  tD)]

Î´t(cid:105)

(cid:104)(cid:88)

tâˆˆTs

By deï¬nition  a belief is a function b : S T Ã— {0  1} â†’ [0  1] such that(cid:80)

The weight w reï¬‚ects social/medical policy; for instance  w might be chosen to minimize cost subject
to some accepted tolerance in delay (Further discussion on this is in Section 4).
Comment The standard decision theory methods [18]-[21] used in screening [7][9] cannot be used
to solve the above problem. In standard POMDPs  the interval between two decision epochs (in this
case  screening times) is ï¬xed exogenously; in standard POSMDPs  the time between two decision
epochs is the sojourn time for the underlying core-state process. In our setting  the time between two
decision epochs depends on the action (follow-up date)  the external information process  and the
state trajectory. In standard POMDPs (POSMDPs) the cost incurred in a decision epoch depend on
the current state  while in the above problem the delay cost depends on the state trajectory. Moreover 
in our setting the disease state trajectory is not restricted to a Markovian or Semi-Markovian process.
3 Proposed Approach
Beliefs By a belief b we mean a probability distribution over the pairs consisting of state trajectories
and a label l for the diagnosis: l = 1 if the patient has been diagnosed with the disease  l = 0 otherwise.
(cid:126)s l b((cid:126)s  l) = 1 but it is often
convenient to view a belief as a vector. Beliefs are updated using Bayesian updating every time there
is a new observation (test outcomes  patient arrival  external information). Knowledge of beliefs
will be sufï¬cient to solve the optimization problem (1); see the Appendix C in the Supplementary
Materials. We write B for the space of all beliefs.
Bellman Equations To solve (1) we will formulate and solve the Bellman equations. To this end 
we begin by deï¬ning the various components of the Bellman equations. Fix a time t. The cost ËœC
incurred at time t depends on what happens at that time: i) if the patient (with diagnosis status l = 0
before the test) is tested and found to have acquired the disease  the cost is the sum of the cost of
testing and the cost of delay  ii) if the patient has the disease and is not detected  then the cost of delay
is incurred in the time slot T   and iii) if the patient does not have the disease  then the cost incurred in
time slot t depends on whether a test was done in time slot t or not. We write these cases below.

ï£±ï£²ï£³wC(t âˆ’ tD; tD) + (1 âˆ’ w)Î´tI(z (cid:54)= âˆ…)

wC(T âˆ’ tD; tD)
(1 âˆ’ w)Î´tI(z (cid:54)= âˆ…)

ËœC((cid:126)s  t  z  l) =

t â‰¤ T  l = 0  z âˆˆ Z +
t = T  l = 0
otherwise

(2)

A recommendation plan Ï„ : Z â†’ T maps the observation z at the end of time slot t to the next
scheduled follow-up time. Note that the recommendation plan is deï¬ned for a time t and is different
than the policy. Denote the probability distribution over the observations (test outcome z  duration to
the next arrival ËœÏ„  and the external information at the next arrival time y) conditional on the current

belief b and the current recommendation plan Ï„ by P r(z  y  ËœÏ„(cid:12)(cid:12)b  Ï„   x). The belief b is updated to

4

Ë†b in the next arrival time ËœÏ„ based on the observations  current recommended plan and the current
beliefs using Bayesian updating as Ë†b((cid:126)s  l) = P r((cid:126)s  l|b  Ï„   y  z  ËœÏ„   x).
The optimal values for the objective in (2) starting from different initial beliefs can be expressed in
terms of a value function V : B Ã— {1  ...  T + 1} â†’ R. The value function at time t when the patient
is screened solves the Bellman equation:

(cid:104)(cid:88)

âˆ’b((cid:126)s  l)P r(z|(cid:126)s  x)(cid:2) ËœC((cid:126)s  t  z  l)(cid:3) +

(cid:88)

P r(z  y  ËœÏ„(cid:12)(cid:12)b  Ï„   x)V(cid:0)Ë†b  t + ËœÏ„(cid:1)(cid:105)

(3)

V (b  t) = max

Ï„

(cid:126)s l z

z ËœÏ„  y

We deï¬ne V (b  T + 1) = 0 for all beliefs. Note that the computation of the ï¬rst term in the RHS
of (3) has a worst case computation time of |S|T . Therefore  solving for exact V (b  T ) that satisï¬es
(3) is computationally intractable when T is large. Next  we derive a useful property of the value
function. (The proof of this and all other results are in the Appendix D-F of the Supplementary
Material.).
Lemma 1 For every t  the value function V (b  t) is the maximum of a ï¬nite family of functions that
are linear in the beliefs b. In particular  the value function is convex and piecewise linear.
The above property was shown for POMDPs in [39]  we use the same ideas to extend it to our setup.

3.1 Constructing the Exactly Optimal Policy
Every linear function of beliefs is of the form Î±âˆ—b for some vector Î±. (We view Î±  b as column
vectors and write Î±âˆ— for the transpose.) Hence Lemma 1 tells us that there is a ï¬nite set of vectors
Î“(t) such that V (b  t) = maxÎ±âˆˆÎ“(t) Î±âˆ—b. We refer to Î“(t) as the set of alpha vectors. In view of
Lemma 1  to determine the value functions we need only determine the sets of alpha vectors. If we
substitute the expression V (b  t) = maxÎ±âˆˆÎ“(t) Î±âˆ—b into (3)  then we obtain a recursive expression
for Î“(t) in terms of Î“(t + 1). By deï¬nition  the value function at time T + 1 is identically 0 so
Î“(T + 1) = {0}  where 0 is the |S T Ã—{0  1}| dimensional zero vector  so we have an explicit starting
point for this recursive procedure. There is an optimal action associated with each alpha vector.
The action corresponding to the optimal alpha vector at a certain belief is the output of the optimal
action given that belief  and so constructing the sets of alpha vectors yields the optimal policy; the
details of the algorithm are in the Algorithm 3 in the Appendix A of the Supplementary Materials.
Unfortunately  the algorithm to compute the sets of alpha vectors is computationally intractable (as
expected). We therefore propose an algorithm that is tractable to compute an approximately optimal
policy.

3.2 Constructing the Approximately Optimal Policy

Point-Based Value Iteration (PBVI) approximation algorithms are known to work well for standard
POMDPs [18]. These algorithms rely on choosing a ï¬nite set of belief vectors and constructing alpha
vectors for these belief vectors and their success depends very much on the efï¬cient construction of
the set of belief vectors. The standard approaches [18] for belief construction are not designed to
cope with settings like ours when beliefs lie in a very high dimensional space; in our setup belief has
|S T Ã— {0  1}| dimensions. In Algorithm 1 (pseudo-code in the Appendix A of the Supplementary
Materials)  we ï¬rst construct a lower dimensional belief space by sampling trajectories that are more
likely to occur for the disease and then sampling the set of beliefs in the lower dimensional space that
are likely to occur over the course of various screening policies. The key steps for Algorithm 1 are
1. Sample typical physiological state trajectories Sample a set ËœS âŠ‚ S T of K physiological
trajectories from the distribution P r((cid:126)s|x).
2. Construct the set of reachable belief vectors Say that a belief vector b2 is reachable from
the belief vector b1 if it can be derived by Bayesian updating on the basis of some underlying
screening policy. We construct the sets of belief vectors that can be reached under different screening
policies. For the ï¬rst time slot  we start with a belief vector that lies in the space ËœS Ã— {0  1} given as
P r((cid:126)s|x)/P r( ËœS|x)  âˆ€(cid:126)s âˆˆ ËœS  l = 0. For subsequent times  we select the beliefs that are encountered
under random exploration of the actions (recommendation of future test dates). In addition to using
random exploration  we can choose actions determined from a set of policies such as the clinical
policies used in practice [27] [28] [47] to construct the set of reachable belief vectors.

5

Denote the set of belief vectors constructed at time t by Â¯B[t] and the set of all such beliefs as
Â¯B = { Â¯B[t] âˆ€t}. We carry out point-based value backups on these beliefs Â¯B (see Algorithm
2 in the Appendix A of the Supplementary Materials)  to construct the alpha vectors and thus
the approximately optimal policy. Henceforth  we refer to our approach (Algorithm 1 and 2) as
DPSCREEN.
Computational Complexity

O(cid:0)T (B)2T 2K|Y||Z|(cid:1) steps  where B = maxt | Â¯B[t]| is the maximum over the number of

the policy requires

computation of

The worst

case

points sampled by the Algorithm 1 for any time slot t. The complexity can be reduced by restricting
the space of actions; e.g. by bounding the amount of time allowed between successive screenings.
Moreover  the proposed algorithms can be easily parallelized (many operations carried inside the
iterations in Algorithm 2 can be done parallel)  thus signiï¬cantly reducing computation time.
Approximation Error Because we only sample a ï¬nite number of trajectories  the policy we
construct is not optimal but we can bound the loss of performance in comparison to the exactly optimal
policy and hence justify the term â€œapproximately optimal policy.â€ Deï¬ne the approximation error to
be the difference between the value achieved by the exact optimal policy (solution to (1)) and the value
achieved by the approximately optimal policy (output from Algorithm 2). As a measure of the density
of sampling of the belief simplex we set â„¦( Â¯B) = Î¶ maxtâˆˆT maxB minbâˆˆ Â¯B[t] ||b âˆ’ b
(cid:48)||1  where Î¶ is
a constant that measures the maximum expected loss that can occur in one time slot. We make a few
assumptions for the proposition to follow. The cost for delay is C(td âˆ’ tD; tD) = c(td âˆ’ tD)Î´tD 
where c(d) is a convex function of d. The test outcome is accurate  i.e. no false positives and no
false negatives. The maximum screening interval is bounded by W < T . The time horizon T is
sufï¬ciently large. We show that the loss of performance is bounded by the sampling density.
Proposition 1 The approximation error is bounded above by â„¦( Â¯B).
3.3 Robustness
Estimation Error To this point  it has been assumed that the model parameters are known. In prac-
tice  the model parameters need to be estimated using the observational data. In the next section  we
will give a concrete example of how we estimate these parameters using observational data for breast
cancer. Here we discuss the effect of error in estimation. Suppose that the model being estimated
(cid:48) âˆˆ M  where M is the space of all the possible models (model parametrizations)
(true model) is m
under consideration. (We assume that the probability distribution of the physiological state transition 
the patientâ€™s self-observation outcomes  and the clinicianâ€™s observation outcomes are continuous on
M.) Write L = M Ã— B for the joint space of models and beliefs. Let the estimate of the model be
Ë†m. Let us assume that for every model in M the solution to (1) is unique. Therefore  we can deï¬ne
a mapping Ï„ âˆ— : L Ã— Z Ã— T â†’ T |Z|  where Ï„ âˆ—(l  z  t) is the optimal recommended screening time
at l  at time t following z. For a ï¬xed model m  Ï„ âˆ—((m  b)  z  t) is the maximizer in (3).
Theorem 1. There is a closed lower dimensional set E âŠ‚ L such that the function Ï„ âˆ— is locally
constant on the complement of E.
Theorem 1 implies that  with probability 1  if the model estimate Ë†m and the true model m(cid:48) are
sufï¬ciently close  then the actions recommended by the exactly optimal policies for both models are
identical. Therefore  the impact of estimation error on the exactly optimal policy is minimal. However 
we construct approximately optimal policies. We can combine these conditions with Proposition 1 to
say that if the approximation error â„¦( Â¯B) goes to zero  then the approximately optimal policy (for Ë†m)
(cid:48)
will also converge to the exactly optimal policy for true model m
Personalization: Figure 1 provides a graphical representation of the way in which DPSCREEN
is personalized to the patients. We consider three Patients. The disease model for each patient
is given by the ex ante survival curve (the probability of not becoming diseased by a given time).
As shown in the graphs  the survival curves for Patients 1  2 are the same; the survival curve for
Patient 3 begins below the survival curve for Patients 1  2 but is ï¬‚atter and so eventually crosses
the survival curve for Patients 1  2. All three patients are screened at date 1; for all three the test
outcome is z = Low. Hence the belief (risk assessment) for all three patients decreases. As a result 
Patients 1  2 are scheduled for next screening at date 4 but Patient 3  who has a lower ex ante survival
probability  is scheduled for next screening at date 3. Thus  the policy is personalized to the ex ante
risk. However  at date 2  all three patients experience an external information shock which causes
them to be screened early. The test outcome for Patient 1 is z = Medium so Patient 1 is assessed
to be at higher risk and is scheduled for next screening at date 3; the test outcome for Patient 2 is

.

6

Figure 1: Illustration of dynamic personalization

z = Low so Patient 2 is assessed to be at lower risk and is scheduled for next screening at date 5.
Thus the policy is personalized to the dynamic history. The test outcome for Patient 3 is z = Low
and Patient 3â€™s ex ante survival probability is higher so Patient 3â€™s risk is assessed to be very low  and
Patient 3 is scheduled for next screening at date 6. Thus the policy adjusts to time-varying model
parameters.

4

Illustrative Experiments

Here we demonstrate the effectiveness of our policy in a real setting: screening for breast cancer.
Description of the dataset: We use a de-identiï¬ed dataset (from Athena Health Network [22])
of 45  000 patients aged 60-65 who underwent screening for breast cancer. For most individuals
we have the following associated features: age  the number of family members with breast cancer 
weight  etc. Each patient had at least one mammogram; some had several. (In total  there are 84 000
mammograms in the dataset.) If the patients had a positive mammogram  a biopsy is carried out.
Further description of mammogram output is in the Appendix G of the Supplementary Materials.
Model description We model the disease progression using a two-state Markov model: S = {H  D}
(H = Healthy  D = Disease/Cancer). Given patient features x  the initial probability of cancer is
pin(x) and the probability of transition from the H to D is ptr(x). The external information Y
is the size (perhaps 0) of a breast lump  based on the patientâ€™s own self-examination. In view
of the universal growth law for tumor described in [23]  we model Y (t) = g(t) + (t)  where
g(t) = (1 âˆ’ eâˆ’Î¹(tâˆ’ts))I(t > ts) is the size of the tumor and ts is the time at which patient actually
develops cancer (the lump exists)  (t) is a zero mean white noise process with variance Ïƒ2 and I() is
the indicator function. If the lump size Y exceeds the threshold Ëœy  then the patient visits the clinician 
where tests are carried out. The set of test outcomes is Z = {âˆ…  1  2  3}  where z = âˆ… when no test is
done  z = 1 when the mammogram is negative and no biopsy is done  z = 2 when the mammogram
is positive and the biopsy is negative  z = 3 when both mammogram and biopsy is positive.
Model Estimation We use the speciï¬city and sensitivity for the mammogram from [7]. Each patient
has a different (initial) risk for developing cancer; we compute the risk scores using the Gail model
[24]  which we use as the feature x. We assumed pin(x) and ptran(x) are logistic functions of x. We
use standard Markov Chain Monte Carlo methods to estimate these functions pin(x) and ptran(x)
(further details in the Appendix G of the Supplementary Materials). We assume that each woman has
one self-examination per month [25] [26]. We use the value Î¹ = 0.9 as stated in [23]. We estimate
the parameters for the self-examinations Ïƒ = 0.43 and Ëœy = 1 on the basis of the values of sensitivity
and speciï¬city for the self-examination from the literature [43]. In the comparisons to follow  we

7

ğ‘§=ğ¿ğ‘œğ‘¤TimeBelief	DiseasePatient	112345ğ‘§=ğ¿ğ‘œğ‘¤TimeBelief	Diseaseğ‘§=ğ¿ğ‘œğ‘¤ğ‘¡â€™=512345ğ‘§=ğ¿ğ‘œğ‘¤Time	Belief	Diseaseğ‘§=ğ¿ğ‘œğ‘¤12345ğ‘¡â€™:prescribed	next	arrival	time666ğ‘¡â€™	=4	ğ‘¡â€™	=4	ğ‘¡â€™	=3	ğ‘¡â€™	=3	ğ‘¡â€™	=6	Patient	1	and	2:	Personalization	through	historiesSame	features 	different	histories	â†’	different	screeningPatient	2	and	3:	Personalization	through	featuresSame	history 	different	hazard	rates	â†’	different	screeningğ¿ğ‘€ğ»ğ¿ğ‘€ğ»ğ¿ğ‘€ğ»ğ‘§:test	outcomesğ‘§=ğ‘€ğ‘’ğ‘‘ğ‘–ğ‘¢ğ‘šSurvival	probabilitySurvival	probabilitySurvival	probabilityPatient	2Patient	3will also analyze the setting when there are no self-examinations. We divide the population into two
risk groups; the Low risk group consists of patients whose prior estimated risk of developing cancer
within ï¬ve years is less than 5%; the High risk group consists of patients whose prior estimated risk
exceeds 5%.
Performance Metrics  Objective and Benchmarks: Our objective is to minimize the number
of screenings subject to a constraint on expected delay cost. We assume the delay cost is linear:
C(td âˆ’ tD  tD) = td âˆ’ tD. To derive the solution to this constrained problem from construction 
which minimizes the weighted sum of screening cost and delay cost  we solve the weighted problem
for some weight w  and then tune w to select the policy that minimizes the number of screenings
subject to a constraint on expected delay cost. For comparison purposes  we take the constraint
on expected delay cost to be the expected delay that arises from current clinical practice (annual
screening in the US [27][28]  biennial screening in some other countries [29]). (Because our objective
is to minimize the number of screenings  we take the cost of each screening to be 1  whether or not a
biopsy is performed.)
Comment At this point  we remind that existing frameworks [7][9][10] cannot be used to solve for
the optimal screening policy in the above setup because: i) the costs incurred (delay) depends on
the state trajectory and not just the current state  and ii) the lump growth model and the patientâ€™s
self-examination of the lump is not easy to incorporate in these works.
Comparisons with clinical screening policies: We compare our constructed policies (for the two
groups)  with and without self-examination  in terms of three metrics: i) E[N|R]: the expected
number of tests per year  conditional on the risk group; ii) E[âˆ†|R]: the expected delay  conditional
on the risk group; iii) E[âˆ†|R  D]: the expected delay  conditional on the risk group and the patient
actually developing cancer. Because E[âˆ†|R] is the expected unconditional delay  it accounts for
patients who do not develop cancer as well as for patients who do have cancer; because most patients
do not develop cancer  E[âˆ†|R] is small. We show the comparisons with the annual policies in Table 1;
we show the comparisons with biennial screening in the Appendix G of the Supplementary Materials.
In Table 1 we compare the performance of DPSCREEN (with and without self-examination) for Low
and High risk groups against the current clinical policy of annual screening. For both risk groups 
the proposed policy achieves approximately the same expected delay as the benchmark policy while
doing many fewer tests (in expectation). With self-examinations  the expected reduction in number of
screens is 57-68% (depending on risk group); even without self-examinations  the expected reduction
in number of screens is 28-45% percent (depending on risk group).
In Table 2 we contrast the difference in DPSCREEN across the two risk groups. To keep the
comparison fair  we ï¬x the tolerance in the delay to a ï¬xed value. The proposed policy is personalized
as it recommends signiï¬cantly fewer tests to the low risk patients in contrast to the high risk patients.
Impact of the type of disease: We have so
far considered breast cancer as an example
and assumed linear delay costs. For some dis-
eases (such as Pancreatic cancer [30][5]) the
survival probability decreases very quickly with
the delay in detection and therefore it might
be reasonable to assume a cost of delay that
is strictly convex (such as quadratic costs) in
delay time for some disease. In Figure 2  we
show that for a ï¬xed risk group and for the same
weights the policy constructed using quadratic
costs is much more aggressive in testing. More-
over  the regime of operation of the policy (the
points achieved by the policy in the 2-D plane
E[N|R  Cost] vs E[âˆ†|R  Cost]) can vary a lot depending on the choice of cost function even though
the same weights are used. Therefore  the cost should be chosen based on the disease.

Figure 2: Impact of the type of disease

5 Related Works
In Section 2  following the equation (1)  we compared our methods with frameworks to some general
frameworks in decision theory [18]-[21]. Next  we compare with other relevant works.

8

E["jR;Cost]months00.20.40.60.81E[NjR;Cost]00.511.522.53Highrisk LinearcostHighrisk QuadraticcostLowrisk LinearcostLowrisk Quadraticcostw=0.5w=0.3w=0.3w=0.9w=0.5w=0.9w=0.3w=0.5w=0.9w=0.3w=0.9w=0.5Table 1: Comparison of the proposed policy with annual screening for both high and low risk group.

Risk
Group
Low
High

Metrics
E[N|R]  E[âˆ†|R]  E[âˆ†|R  D]
E[N|R]  E[âˆ†|R]  E[âˆ†|R  D]

DPSCREEN with
self-examination
0.32  0.23  9.2
0.43  0.50  6.7

DPSCREEN w/o
self-examination
0.55  0.23  9.2
0.72  0.52 7.07

Annual

1  0.24  9.6
1  0.52  7.07

Table 2: Comparison of the proposed policies across different risk groups

Risk
Group

Low
High

DPSCREEN with self-examination DPSCREEN w/o self-examination
E[N|R]  E[âˆ†|R]  E[âˆ†|R  D]
0.12  0.33  13.7
0.80  0.35  4.73

E[N|R]  E[âˆ†|R]  E[âˆ†|R  D]
0.32  0.33  13.7
1.09  0.35  4.73

Screening frameworks for different diseases in operations research: Many works have focused
on optimizing population-based screening schedules  which are not personalized (See [42] and
references therein). In [7] [9] the authors develop personalized POMDP based screening models.
The underlying disease evolution (breast and colon cancer) is assumed to follow a Markov process.
External information process such as self-exams and the test outcomes over time are assumed to
follow a stationary i.i.d process given the disease process. In [10] authors develop personalized
screening models based on principles of Bayesian design for maximizing information gain (based
on [40]). The underlying disease model (cardiac disease) is a dynamic (two-state) survival model
and the cost of misdetection is a constant and does not depend on the delay. The test outcomes are
modeled using generalized linear mixed effects models  and there is no external information process.
To summarize  all of the above methods rely on very speciï¬c models for their disease  test outcomes 
and external information  while our method imposes much less restrictions on the same.
Screening frameworks for different diseases in medical literature: The Medical research litera-
ture on screening (e.g.  Cancer Intervention and Surveillance Modelling Network  US preventive
services task force  etc.) relies on stochastic simulation based methods: ï¬x a disease model and a
set of screening policies to be compared; for each policy in the set  simulate outcome paths from
the model; compare across the set of policies [44]-[48]. The clinical guidelines for screening issued
by the US preventive services task force [47][49] for colon cancer cancers are created based on the
MISCAN-COLON [46] model for colon cancer. Simulations were carried out to compare different
screening policies suggested by experts for that speciï¬c disease model- MISCAN-COLON. This
approach allows more realistically complex models but it only compares a ï¬xed set of policies  all of
which may be far from optimal.
Controlled Sensing: In controlled sensing [21][34][38] the problem of sensor scheduling requires
deciding which sensor to use and when; this problem is similar the personalized screening problem
studied here. In these works [21][34][38]  the main focus is to exploit (or derive) structural properties
of the process being sensed and the cost functions such that the exactly optimal sensing schedule is
easy to characterize and compute. The structural assumptions such as the process that is sampled is
stationary and Markov make these works less suited for personalized screening.

6 Conclusion

In this work  we develop a novel methodology for constructing personalized screening policies that
balance the cost of screening against the cost of delay in detection of disease. The disease is modeled
as an arbitrary ï¬nite state stochastic process with an absorbing disease state. Our method incorporates
the possibility of external information  such as self-examination or discovery of co-morbidities  that
may trigger arrival of the patient to the clinician in advance of a scheduled screening appointment.
We use breast cancer data to develop the disease model. In comparison with current clinical policies 
our personalized screening policies reduce the number of screenings performed while maintaining
the same delay in detection of disease.

9

7 Acknowledgements

This work was supported by the Ofï¬ce of Naval Research (ONR) and the National Science Foundation
(NSF) (Grant number: 1533983 and Grant number: 1407712).

References

[1] Siu  A. L. (2016). Screening for breast cancer: US Preventive Services Task Force recommenda-
tion statement. Annals of internal medicine  164(4)  pp.279-296.
[2] Canto  M. et.al. (2013). International Cancer of the Pancreas Screening (CAPS) Consortium
summit on the management of patients with increased risk for familial pancreatic cancer  Gut  62(3) 
pp.339-347.
[3] Wilson  J. et.al. (1968). Principles and practice of screening for disease.
[4] Jemal  A. et.al. (2010). Cancer statistics  CA: a cancer journal for clinicians  60(5)  pp.277-300.
[5] Rulyak  S. J. et.al. (2003). Cost-effectiveness of pancreatic cancer screening in familial pancreatic
cancer kindreds  Gastrointestinal endoscopy  57(1)  pp.23-29.
[6] Pace  L. E.  & Keating  N. L. (2014). A systematic assessment of beneï¬ts and risks to guide breast
cancer screening decisions. Jama  311(13)  1327-1335.
[7] Ayer  T. et.al. (2012). OR forumâ€”a POMDP approach to personalize mammography screening
decisions. Operations Research  60(5)  pp.1019-1034.
[8] Maillart  L. M. et.al. (2008). Assessing dynamic breast cancer screening policies. Operations
Research  56(6)  pp.1411-1427.
[9] Erenay  F. S. et.al. (2014). Optimizing colonoscopy screening for colorectal cancer prevention
and surveillance  Manufacturing & Service Operations Management  16(3)  pp.381-400.
[10] Rizopoulos  D. et.al. (2015). Personalized screening intervals for biomarkers using joint models
for longitudinal and survival data. Biostatistics  17(1)  pp.149-164.
[11] Cox  D. R. (1992). Regression models and life-tables. In Breakthroughs in statistics. Springer
New York.
[12] Miller Jr  R. G. (2011). Survival analysis John Wiley & Sons.
[13] Crowder  M. J. (2001). Classical competing risks. CRC Press.
[14] Lee  M. L. T. et.al. (2003). First hitting time models for lifetime data  Handbook of statistics  23 
pp.537-543.
[15] Cox  D. R. (1992). Regression models and life-tables. In Breakthroughs in statistics. Springer
New York  pp. 527-541.
[16] Si  X. S. et.al. (2011). Remaining useful life estimationâ€“A review on the statistical data driven
approaches. European journal of operational research  213(1)  pp.1-14.
[17] Lee  M. L. T. et.al. (2006). Threshold regression for survival analysis: modeling event times by
a stochastic process reaching a boundary. Statistical Science  pp.501-513.
[18] Pineau  J. et.al. (2003). Point-based value iteration: An anytime algorithm for POMDPs  n Joint
Conference on Artiï¬cial Intelligence  3  pp. 1025-1032.
[19] Kim  D. et.al. (2011). Point-based value iteration for constrained POMDPs  in Joint Conference
on Artiï¬cial Intelligence  pp. 1968-1974.
[20] Yu  H. (2006). Approximate solution methods for partially observable Markov and semi-Markov
decision processes  Doctoral dissertation  Massachusetts Institute of Technology.
[21] Krishnamurthy  V. (2016). Partially Observed Markov Decision Processes. Cambridge University
Press.

10

[22] Elson  S. L. et.al. (2013). The Athena Breast Health Network: developing a rapid learning system
in breast cancer prevention  screening  treatment  and care. Breast cancer research and treatment   
140(2)  pp.417-425.
[23] Guiot  C. et.al. (2003). Does tumor growth follow a â€œuniversal lawâ€?  Journal of theoretical
biology  225(2)  pp.147-151.
[24] Gail  M. H. et.al. (1989). Projecting individualized probabilities of developing breast cancer for
white females who are being examined annually. Journal of the National Cancer Institute  81(24) 
1879-1886.
[25] Baxter  N. (2002). Breast self-examination  Canadian Medical Association Journal  Chicago 
166(2)  pp.166-168.
[26] Thomas  D. B. et.al.(2002). Randomized trial of breast self-examination in Shanghai: ï¬nal
results. Journal of the National Cancer Institute  94(19)  1445-1457.
[27] Oefï¬nger  K. C. et.al. (2015). Breast cancer screening for women at average risk: 2015 guideline
update from the American Cancer Society. Jama  314(15)  1599-1614.
[28] Nelson  H. D. et.al. (2009). Screening for breast cancer: an update for the US Preventive
Services Task Force. Annals of internal medicine  151(10)  727-737.
[29] Klabunde  C. N. et.al. (2007). Evaluating population-based screening mammography programs
internationally. In Seminars in breast disease  International Breast Cancer Screening Network  10 (2) 
pp. 102-107.
[30] Sener  S. F. et.al. (1999). Pancreatic cancer: a report of treatment and survival trends for 100 313
patients diagnosed from 1985â€“1995  using the National Cancer Database. Journal of the American
College of Surgeons  189(1)  pp.1-7.
[31] Armstrong  K. et.al. (2007). Screening mammography in women 40 to 49 years of age: a
systematic review for the American College of Physicians. Annals of internal medicine  146(7) 
516-526.
[32] Liebman  M. N. (2007). Personalized medicine: a perspective on the patient  disease and causal
diagnostics  171-174.
[33] Mandelblatt  J. S. et.al. (1992). Breast cancer screening for elderly women with and without
comorbid conditions. Ann Intern Med  116  722-730.
[34] Alaa  A. M. et.al. (2016). Balancing suspense and surprise: Timely decision making with
endogenous information acquisition  in Advances in Neural Information Processing Systems (NIPS) 
pp. 2910-2918.
[35] Schulam  P. et.al.
Processing Systems (NIPS)  pp. 4709-4717.
[36] Rizopoulos  D. (2011). Dynamic Predictions and Prospective Accuracy in Joint Models for
Longitudinal and Time to Event Data. Biometrics  67(3)  819-829.
[37] Meira-Machado  L. et.al. (2006). Nonparametric estimation of transition probabilities in a
non-Markov illnessâ€“death model. Lifetime Data Analysis  12(3)  325-344.
[38] Krishnamurthy  V. (2017). POMDP Structural Results for Controlled Sensing. arXiv preprint
arXiv:1701.00179.
[39] Smallwood  R. D.  & Sondik  E. J. (1973). The optimal control of partially observable Markov
processes over a ï¬nite horizon. Operations research  21(5)  1071-1088.
[40] Verdinelli  I. et.al. (1992). Bayesian designs for maximizing information and outcome  Journal
of the American Statistical Association  87(418)  510-515.
[41] Daskivich  T. J.et.al. (2011). Overtreatment of men with low-risk prostate cancer and signiï¬cant
comorbidity  Cancer  117(10)  2058-2066.
[42]Alagoz  O et.al. (2011). Operations research models for cancer screening  Wiley Encyclopedia
of Operations Research and Management Science.

(2016). Disease Trajectory Maps  in Advances In Neural Information

11

[43] Elmore  J. G. et.al. (2005). Efï¬cacy of breast cancer screening in the community according to
risk level. Journal of the National Cancer Institute  97(14)  1035-1043.
[44] Vilaprinyo et.al (2014). Cost-effectiveness and harm-beneï¬t analyses of risk-based screening
strategies for breast cancer  PloS one. 9(2)  p.e86858.
[45] Trentham-Dietz et.al. (2016) Tailoring Breast Cancer Screening Intervals by Breast Density
and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes
Risk-Based Breast Cancer Screening Intervals  Annals of Internal Medicine  165(10)  pp.700-712.
[46] Loeve  F. et.al (1999). The MISCAN-COLON simulation model for the evaluation of colorectal
cancer screening. Computers in Biomedical Research  32(1)  pp.13-33.
[47] Zauber  A. G. et.al. (2009) Evaluating Test Strategies for Colorectal Cancer Screening: A
Decision Analysis for the US Preventive Services Task Force. Annals of Internal Medicine  149(9) 
pp.659-669.
[48] Frazier  A. L et.al. (2000) Cost-effectiveness of screening for colorectal cancer in the general
population  JAMA  284(15)  pp.1954-1961.
[49] Whitlock et.al. (2008) Screening for Colorectal Cancer: A Targeted  Updated Systematic Review
for the US Preventive Services Task Force Screening for Colorectal Cancer. Annals of Internal
Medicine  149(9)  pp.638-658.
[50] Alaa  A.M. et.al. (2016). Conï¬dentCare: A Clinical Decision Support System for Personalized
Breast Cancer Screening  accepted and to appear in IEEE Transactions on Multimedia-Special Issue
on Multimedia-based Healthcare  18(10)  pp.1942-1955.

12

,Christian Albers
Maren Westkott
Klaus Pawelzik
Kartik Ahuja
William Zame
Mihaela van der Schaar
Hongteng Xu
Wenlin Wang
Wei Liu
Lawrence Carin